Legit short squeezes are fairly rare. But when they do occur, shareholders of heavily shorted equities can generate enormous returns on capital in an exceedingly short period.
Which under-the-radar equity stands out as a top short-squeeze candidate right now? The developmental biotech Anavex Life Sciences (NASDAQ: AVXL) ticks off some of the most important boxes in this regard.
First off, the biopharma's shares have attracted an increasing number of short-sellers over the prior six months, resulting in nearly a quarter of its float being sold short as of Jan. 13, 2023. Secondly, and perhaps most importantly, Wall Street analysts -- at least those with a bullish view on the company -- think Anavex stock is massively undervalued right now.
For further details see:
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run